400 related articles for article (PubMed ID: 24201303)
41. Prophylactic catheter ablation for induced monomorphic ventricular tachycardia in patients with implantable cardioverter defibrillators as primary prevention.
Hayashi T; Fukamizu S; Hojo R; Komiyama K; Tanabe Y; Tejima T; Soejima K; Nishizaki M; Hiraoka M; Ako J; Momomura S; Sakurada H
Europace; 2013 Oct; 15(10):1507-15. PubMed ID: 23603305
[TBL] [Abstract][Full Text] [Related]
42. The effect of gender on mortality or appropriate shock in patients with nonischemic cardiomyopathy who have implantable cardioverter-defibrillators.
Chen HA; Hsia HH; Vagelos R; Fowler M; Wang P; Al-Ahmad A
Pacing Clin Electrophysiol; 2007 Mar; 30(3):390-4. PubMed ID: 17367359
[TBL] [Abstract][Full Text] [Related]
43. Clinical impact of nonsustained ventricular tachycardia recorded by the implantable cardioverter-defibrillator in patients with hypertrophic cardiomyopathy.
Francia P; Santini D; Musumeci B; Semprini L; Adduci C; Pagannone E; Proietti G; Volpe M; Autore C
J Cardiovasc Electrophysiol; 2014 Nov; 25(11):1180-7. PubMed ID: 25066044
[TBL] [Abstract][Full Text] [Related]
44. Statin use was associated with reduced mortality in both ischemic and nonischemic cardiomyopathy and in patients with implantable defibrillators: mortality data and mechanistic insights from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT).
Dickinson MG; Ip JH; Olshansky B; Hellkamp AS; Anderson J; Poole JE; Mark DB; Lee KL; Bardy GH;
Am Heart J; 2007 Apr; 153(4):573-8. PubMed ID: 17383296
[TBL] [Abstract][Full Text] [Related]
45. Evaluation of the Impact of a Chronic Total Coronary Occlusion on Ventricular Arrhythmias and Long-Term Mortality in Patients With Ischemic Cardiomyopathy and an Implantable Cardioverter-Defibrillator (the eCTOpy-in-ICD Study).
van Dongen IM; Yilmaz D; Elias J; Claessen BEPM; Delewi R; Knops RE; Wilde AAM; van Erven L; Schalij MJ; Henriques JPS
J Am Heart Assoc; 2018 May; 7(10):. PubMed ID: 29720502
[TBL] [Abstract][Full Text] [Related]
46. Effect of long-detection interval vs standard-detection interval for implantable cardioverter-defibrillators on antitachycardia pacing and shock delivery: the ADVANCE III randomized clinical trial.
Gasparini M; Proclemer A; Klersy C; Kloppe A; Lunati M; Ferrer JB; Hersi A; Gulaj M; Wijfels MC; Santi E; Manotta L; Arenal A
JAMA; 2013 May; 309(18):1903-11. PubMed ID: 23652522
[TBL] [Abstract][Full Text] [Related]
47. Long-term follow-up of implantable cardioverter-defibrillator for secondary prevention in chagas' heart disease.
Martinelli M; de Siqueira SF; Sternick EB; Rassi A; Costa R; Ramires JA; Kalil Filho R
Am J Cardiol; 2012 Oct; 110(7):1040-5. PubMed ID: 22727179
[TBL] [Abstract][Full Text] [Related]
48. Prognosis among healthy individuals discharged with a primary diagnosis of syncope.
Ruwald MH; Hansen ML; Lamberts M; Hansen CM; Vinther M; Køber L; Torp-Pedersen C; Hansen J; Gislason GH
J Am Coll Cardiol; 2013 Jan; 61(3):325-32. PubMed ID: 23246392
[TBL] [Abstract][Full Text] [Related]
49. Effect of Novel Programming on Inappropriate Implantable Cardioverter-Defibrillator Therapy in Patients With Very Low Ejection Fraction (from A MADIT-RIT).
Jawaid A; Chokshi M; Zareba W; Schuger C; Daubert J; McNitt S; Singh J; Goldenberg I; Kutyifa V
Am J Cardiol; 2022 Nov; 182():32-39. PubMed ID: 36075757
[TBL] [Abstract][Full Text] [Related]
50. Use of the wearable cardioverter defibrillator in high-risk cardiac patients: data from the Prospective Registry of Patients Using the Wearable Cardioverter Defibrillator (WEARIT-II Registry).
Kutyifa V; Moss AJ; Klein H; Biton Y; McNitt S; MacKecknie B; Zareba W; Goldenberg I
Circulation; 2015 Oct; 132(17):1613-9. PubMed ID: 26316618
[TBL] [Abstract][Full Text] [Related]
51. Multicenter experience with a pectoral unipolar implantable cardioverter-defibrillator. Active Can Investigators.
Bardy GH; Yee R; Jung W
J Am Coll Cardiol; 1996 Aug; 28(2):400-10. PubMed ID: 8800117
[TBL] [Abstract][Full Text] [Related]
52. Clinical predictors and prognostic significance of electrical storm in patients with implantable cardioverter defibrillators.
Brigadeau F; Kouakam C; Klug D; Marquié C; Duhamel A; Mizon-Gérard F; Lacroix D; Kacet S
Eur Heart J; 2006 Mar; 27(6):700-7. PubMed ID: 16421175
[TBL] [Abstract][Full Text] [Related]
53. Safety and efficacy of strategic implantable cardioverter-defibrillator programming to reduce the shock delivery burden in a primary prevention patient population.
Buber J; Luria D; Gurevitz O; Bar-Lev D; Eldar M; Glikson M
Europace; 2014 Feb; 16(2):227-34. PubMed ID: 24108231
[TBL] [Abstract][Full Text] [Related]
54. Implantable cardioverter-defibrillator therapy improves long-term survival in patients with unexplained syncope, cardiomyopathy, and a negative electrophysiologic study.
Sánchez JM; Katsiyiannis WT; Gage BF; Chen J; Faddis MN; Gleva MJ; Smith TW; Lindsay BD
Heart Rhythm; 2005 Apr; 2(4):367-73. PubMed ID: 15851337
[TBL] [Abstract][Full Text] [Related]
55. Implantable cardioverter defibrillators in arrhythmogenic right ventricular dysplasia/cardiomyopathy: patient outcomes, incidence of appropriate and inappropriate interventions, and complications.
Schinkel AF
Circ Arrhythm Electrophysiol; 2013 Jun; 6(3):562-8. PubMed ID: 23673907
[TBL] [Abstract][Full Text] [Related]
56. Efficacy and safety of implantable cardiac defibrillators for treatment of ventricular arrhythmias in patients with cardiac sarcoidosis.
Kron J; Sauer W; Schuller J; Bogun F; Crawford T; Sarsam S; Rosenfeld L; Mitiku TY; Cooper JM; Mehta D; Greenspon AJ; Ortman M; Delurgio DB; Valadri R; Narasimhan C; Swapna N; Singh JP; Danik S; Markowitz SM; Almquist AK; Krahn AD; Wolfe LG; Feinstein S; Ellenbogen KA
Europace; 2013 Mar; 15(3):347-54. PubMed ID: 23002195
[TBL] [Abstract][Full Text] [Related]
57. Microvolt T-wave alternans identifies patients with ischemic cardiomyopathy who benefit from implantable cardioverter-defibrillator therapy.
Chow T; Kereiakes DJ; Bartone C; Booth T; Schloss EJ; Waller T; Chung E; Menon S; Nallamothu BK; Chan PS
J Am Coll Cardiol; 2007 Jan; 49(1):50-8. PubMed ID: 17207722
[TBL] [Abstract][Full Text] [Related]
58. QT interval variability and spontaneous ventricular tachycardia or fibrillation in the Multicenter Automatic Defibrillator Implantation Trial (MADIT) II patients.
Haigney MC; Zareba W; Gentlesk PJ; Goldstein RE; Illovsky M; McNitt S; Andrews ML; Moss AJ;
J Am Coll Cardiol; 2004 Oct; 44(7):1481-7. PubMed ID: 15464332
[TBL] [Abstract][Full Text] [Related]
59. Incidence and predictors of implantable cardioverter-defibrillator therapy in patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy undergoing implantable cardioverter-defibrillator implantation for primary prevention.
Bhonsale A; James CA; Tichnell C; Murray B; Gagarin D; Philips B; Dalal D; Tedford R; Russell SD; Abraham T; Tandri H; Judge DP; Calkins H
J Am Coll Cardiol; 2011 Sep; 58(14):1485-96. PubMed ID: 21939834
[TBL] [Abstract][Full Text] [Related]
60. Strategic programming of detection and therapy parameters in implantable cardioverter-defibrillators reduces shocks in primary prevention patients: results from the PREPARE (Primary Prevention Parameters Evaluation) study.
Wilkoff BL; Williamson BD; Stern RS; Moore SL; Lu F; Lee SW; Birgersdotter-Green UM; Wathen MS; Van Gelder IC; Heubner BM; Brown ML; Holloman KK;
J Am Coll Cardiol; 2008 Aug; 52(7):541-50. PubMed ID: 18687248
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
